These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36307817)

  • 1. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals.
    Mistler CB; Curley CM; Rosen AO; El-Krab R; Wickersham JA; Copenhaver MM; Khati A; Shrestha R
    J Community Health; 2021 Oct; 46(5):960-966. PubMed ID: 33770334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.
    Pleuhs B; Mistler CB; Quinn KG; Dickson-Gomez J; Walsh JL; Petroll AE; John SA
    J Prim Care Community Health; 2022; 13():21501319211063999. PubMed ID: 35068243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
    Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
    Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
    Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
    BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study.
    Allen ST; O'Rourke A; White RH; Smith KC; Weir B; Lucas GM; Sherman SG; Grieb SM
    AIDS Behav; 2020 Jun; 24(6):1942-1950. PubMed ID: 31853771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurse Practitioner-Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial.
    Khati A; Altice FL; Vlahov D; Eger WH; Lee J; Bohonnon T; Wickersham JA; Maviglia F; Copenhaver N; Shrestha R
    JMIR Res Protoc; 2022 Oct; 11(10):e42585. PubMed ID: 36222826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider Implicit Bias in Prescribing HIV Pre-exposure Prophylaxis (PrEP) to People Who Inject Drugs.
    Dubov A; Krakower DS; Rockwood N; Montgomery S; Shoptaw S
    J Gen Intern Med; 2023 Oct; 38(13):2928-2935. PubMed ID: 36964426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
    Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
    J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missed opportunities for healthcare providers to discuss HIV preexposure prophylaxis with people who inject drugs.
    Vincent W; McFarland W
    Int J Drug Policy; 2022 Dec; 110():103873. PubMed ID: 36252292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study.
    Smith M; Elliott L; Hutchinson SJ; Metcalfe R; Flowers P; McAuley A
    Int J Drug Policy; 2021 Feb; 88():103033. PubMed ID: 33249313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD).
    Herrera MC; Johnson J; Lim S; Morales KH; Wilson JD; Hadland SE; Metzger D; Wood S; Dowshen N
    Drug Alcohol Depend; 2024 Apr; 257():111132. PubMed ID: 38387256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
    Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
    Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Hershow RB; Gonzalez M; Costenbader E; Zule W; Golin C; Brinkley-Rubinstein L
    AIDS Educ Prev; 2019 Aug; 31(4):363-379. PubMed ID: 31361517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.